The prevalence of MS in the United States: a population-based estimate using health claims data

…, JD Campbell, LM Nelson, A Langer-Gould… - Neurology, 2019 - AAN Enterprises
Objective To generate a national multiple sclerosis (MS) prevalence estimate for the United
States by applying a validated algorithm to multiple administrative health claims (AHC) …

Incidence of multiple sclerosis in multiple racial and ethnic groups

A Langer-Gould, SM Brara, BE Beaber, JL Zhang - Neurology, 2013 - AAN Enterprises
Objective: To determine whether the incidence of multiple sclerosis (MS) varies by race/ethnicity
in a multiethnic, population-based cohort. Methods: We conducted a retrospective …

Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies

…, M Gunnarsson, J Hillert, A Langer-Gould… - JAMA …, 2020 - jamanetwork.com
Importance Although highly effective disease-modifying therapies for multiple sclerosis (MS)
have been associated with an increased risk of infections vs injectable therapies interferon …

Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients

…, M Gunnarsson, J Hillert, A LangerGould… - Annals of …, 2020 - Wiley Online Library
Objective Novel, highly effective disease‐modifying therapies have revolutionized multiple
sclerosis (MS) care. However, evidence from large comparative studies on important safety …

[HTML][HTML] B-cell depletion with rituximab in relapsing–remitting multiple sclerosis

…, N Sarkar, S Agarwal, A Langer-Gould… - … England Journal of …, 2008 - Mass Medical Soc
Background There is increasing evidence that B lymphocytes are involved in the pathogenesis
of multiple sclerosis, and they may be a therapeutic target. Rituximab, a monoclonal …

Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis

…, A Brendolan, E Schadt, H Garren, A Langer-Gould… - Nature medicine, 2002 - nature.com
Microarray analysis of multiple sclerosis (MS) lesions obtained at autopsy revealed increased
transcripts of genes encoding inflammatory cytokines, particularly interleukin-6 and -17, …

[HTML][HTML] Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

A Langer-Gould, SW Atlas, AJ Green… - … England Journal of …, 2005 - Mass Medical Soc
<p id="p001">We describe the clinical course of a patient with multiple sclerosis in whom
progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the …

[HTML][HTML] Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data

C Koebnick, AM Langer-Gould, MK Gould… - The Permanente …, 2012 - ncbi.nlm.nih.gov
Background: Data from the memberships of large, integrated health care systems can be
valuable for clinical, epidemiologic, and health services research, but a potential selection bias …

Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome

A Langer-Gould, SM Brara, BE Beaber, C Koebnick - Neurology, 2013 - AAN Enterprises
Objective: To determine whether childhood obesity is a risk factor for developing pediatric
multiple sclerosis (MS) or clinically isolated syndrome (CIS). Methods: Cases were identified …

Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis

A Langer-Gould, SM Huang, R Gupta… - Archives of …, 2009 - jamanetwork.com
… Analysis and interpretation of data: Langer-Gould, Gupta, Greenwood, Van Den Eeden, …
Langer-Gould. Critical revision of the manuscript for important intellectual content: Langer-Gould